Trials / Completed
CompletedNCT03181503
Safety and Efficacy of Nemolizumab in PN
A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
Detailed description
This is a randomized, placebo-controlled, double-blinded, parallel group, multicenter study to evaluate the safety and efficacy of nemolizumab over a 12-week treatment period in patients suffering from prurigo nodularis compared to its placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD14152 Dose A | 3 subcutaneous injections (every 4 weeks during the 12-week treatment period) |
| DRUG | CD14152 placebo | 3 subcutaneous injections (every 4 weeks during the 12-week treatment period) |
Timeline
- Start date
- 2017-10-02
- Primary completion
- 2018-09-26
- Completion
- 2018-09-26
- First posted
- 2017-06-08
- Last updated
- 2020-02-19
- Results posted
- 2020-02-19
Locations
16 sites across 4 countries: Austria, France, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03181503. Inclusion in this directory is not an endorsement.